TY - JOUR
T1 - Applications of Modified Mesenchymal Stem Cells as Targeted Systems against Tumor Cells
AU - Garza-Treviño, Elsa N.
AU - Saavedra Alonso, Santiago
AU - Quiroz-Reyes , Adriana
AU - Delgado-Gonzalez, Paulina
AU - Francisco Islas, José
AU - Rojas Murillo, Juan Antonio
AU - González Villarreal, Carlos Alberto
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/7/16
Y1 - 2024/7/16
N2 - Combined gene and cell therapy are promising strategies for cancer treatment. Given the complexity of cancer, several approaches are actively studied to fight this disease. Using mesenchymal stem cells (MSCs) has demonstrated dual antitumor and protumor effects as they exert massive immune/regulatory effects on the tissue microenvironment. MSCs have been widely investigated to exploit their antitumor target delivery system. They can be genetically modified to overexpress genes and selectively or more efficiently eliminate tumor cells. Current approaches tend to produce more effective and safer therapies using MSCs or derivatives; however, the effect achieved by engineered MSCs in solid tumors is still limited and depends on several factors such as the cell source, transgene, and tumor target. This review describes the progress of gene and cell therapy focused on MSCs as a cornerstone against solid tumors, addressing the different MSC-engineering methods that have been approached over decades of research. Furthermore, we summarize the main objectives of engineered MSCs against the most common cancers and discuss the challenges, limitations, risks, and advantages of targeted treatments combined with conventional ones.
AB - Combined gene and cell therapy are promising strategies for cancer treatment. Given the complexity of cancer, several approaches are actively studied to fight this disease. Using mesenchymal stem cells (MSCs) has demonstrated dual antitumor and protumor effects as they exert massive immune/regulatory effects on the tissue microenvironment. MSCs have been widely investigated to exploit their antitumor target delivery system. They can be genetically modified to overexpress genes and selectively or more efficiently eliminate tumor cells. Current approaches tend to produce more effective and safer therapies using MSCs or derivatives; however, the effect achieved by engineered MSCs in solid tumors is still limited and depends on several factors such as the cell source, transgene, and tumor target. This review describes the progress of gene and cell therapy focused on MSCs as a cornerstone against solid tumors, addressing the different MSC-engineering methods that have been approached over decades of research. Furthermore, we summarize the main objectives of engineered MSCs against the most common cancers and discuss the challenges, limitations, risks, and advantages of targeted treatments combined with conventional ones.
UR - http://www.scopus.com/inward/record.url?scp=85199768349&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85199768349&partnerID=8YFLogxK
U2 - 10.3390/ijms25147791
DO - 10.3390/ijms25147791
M3 - Review article
C2 - 39063032
SN - 1661-6596
VL - 25
JO - International Journal of Molecular Sciences
JF - International Journal of Molecular Sciences
IS - 14
M1 - 7791
ER -